Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesBioxyne Ltd

Bioxyne Ltd

Consumer Defensive Packaged Foods
PortfolioPortfolio WatchlistWatchlist
Company price
None AUD 0.00(0%)
Last update at 2026-11-12T06:45:03.826417Z
Market Cap
213.88M
P/E
23.25

Momentum Score

…

Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingredients and starting materials; plant-based food products, such as non-controlled cannabis extracts and cannabidiol; food grade mushroom extracts/psilocybin; medicinal and prescription cannabis products, including pastilles, vape, oral mucosal oils, flower, and suppositories; SL-NAD+ wafers; MDMA; white label manufactured wellness products; health and wellness supplements; and nootropic and skincare products. It also provides Lactobacillus fermentum VRI-003 PCC, a probiotic formulation for gastrointestinal health and immunity; Progastrim for gut and immune health; and proTract for atopic dermatitis. In addition, the company is involved in the contract manufacturing of final dose form products, including capsules, tablets, inhalables, oral solutions, and herbal preparations; import, export, manufacture, and supply of controlled drugs and medicinal products; research and development of formulations, products, and processes related to health, wellness, and medicine; and provision of telemedicine services. Further, it operates CanXChange, a machine-learning powered B2B wholesale and custody technology platform. The company offers its products to cultivators, manufacturers, pharmacies, clinics, and patients under the Breathe Life Science, Dr Watson, Mirai Solution, and Apothecary CBD brands. It sells its products through wholesale, retail, and online. Bioxyne Limited is headquartered in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.35
Low
1.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bioxyne Ltd is an Australian publicly listed company that has reported activities in the health and biotechnology sector, though current public disclosures on its core operations and pipeline are limited. Long-term growth drivers could include successful product development, regulatory approvals, commercial partnerships and market adoption, which may support revenue growth and licensing opportunities for investors seeking biotech exposure.
Major investment risks include limited publicly available information and transparency, execution and regulatory risk common to life‑science companies, potential need for external financing, and low liquidity typical of small-cap listings.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
47.95M
Revenue Per Share
0.23
Gross Profit TTM
19.69M
Debt / Equity
0.13
ROE
66.14%
Net Debt
-6.13M
ROCE
40.96%
Diluted EPS TTM
0.04

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax 4.90M -13.29M -1.96M -0.24M -0.43M
Minority interest - 0.18M - - 0.05M
Net income 4.90M -13.33M -1.96M -0.24M -0.43M
Selling general administrative 2.09M 2.57M 2.59M 0.88M 0.83M
Selling and marketing expenses 0.41M 0.41M 0.19M 0.02M 0.04M
Gross profit 10.45M 3.40M 1.90M 1.29M 1.08M
Reconciled depreciation - - 0.09M 0.05M 0.05M
Ebit 5.10M -13.29M -2.04M -0.15M -0.27M
Ebitda 5.34M -13.03M -1.96M -0.10M -0.22M
Depreciation and amortization 0.24M 0.26M 0.09M 0.05M 0.05M
Operating income 5.56M -1.66M -1.84M -0.45M -0.37M
Other operating expenses 24.86M 10.98M 7.27M 0.96M 2.72M
Interest expense - 0.04M 0.00M 0.00M 0.00M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.02M 0.02M 0.00M 0.02M 0.02M
Net interest income - 0.02M 0.00M 0.01M 0.02M
Extraordinary items 0.00M -0.53M - - -
Income tax expense -0.84M -0.31M 0.01M 0.04M 0.06M
Total revenue 30.42M 9.33M 5.16M 2.42M 2.11M
Total operating expenses 4.89M 3.36M 4.04M 1.50M 1.43M
Cost of revenue 19.98M 5.93M 3.26M 1.13M 1.03M
Total other income expense net -0.66M -11.63M 0.09M -0.04M -0.09M
Net income from continuing ops - -12.97M -1.96M -0.24M -0.43M
Net income applicable to common shares 4.90M -13.33M -1.96M -0.24M -0.50M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 20.90M 6.70M 17.69M 2.92M 2.75M
Intangible assets 0.39M - 0.03M 0.03M 0.03M
Other current assets 3.03M 0.76M 0.07M 0.07M 0.05M
Total liab 9.53M 3.40M 2.69M 0.98M 0.74M
Total stockholder equity 11.68M 3.61M 15.14M 1.89M 1.95M
Other current liab 3.93M 1.49M 1.48M 0.89M 0.57M
Common stock 21.48M 19.00M 17.55M 62.18M 62.18M
Capital stock - - 17.55M 62.18M 62.18M
Retained earnings -10.70M -15.60M -2.48M -60.48M -60.17M
Other liab - - - -0.00M -
Good will - - 11.57M 11.57M -
Other assets - 0.00M - - -
Cash 7.67M 1.03M 3.85M 2.17M 1.60M
Total current liabilities 8.45M 2.91M 2.69M 0.98M 0.74M
Current deferred revenue - 0.04M - - -0.05M
Net debt -6.13M -0.35M -3.85M -2.17M -1.55M
Short term debt 0.46M 0.18M 0.00M 0.00M 0.05M
Short long term debt total 1.53M 0.67M - - 0.05M
Other stockholder equity - - -15.06M 0.19M -1.94M
Property plant equipment - - 0.09M 0.07M 0.09M
Total current assets 17.14M 5.59M 6.04M 2.82M 2.58M
Net tangible assets - - 3.57M 1.86M 1.81M
Net receivables 2.35M 1.66M 0.90M 0.02M 0.34M
Inventory 4.09M 2.14M 0.99M 0.31M 0.44M
Accounts payable 4.06M 1.19M 1.21M 0.10M 0.18M
Accumulated other comprehensive income 0.91M 0.20M 0.07M 0.19M -0.06M
Non currrent assets other - 0.29M -11.65M - -0.17M
Non current assets total 3.76M 1.11M 11.65M 0.10M 0.17M
Long term debt total - - 0.00M 0.00M 0.00M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -0.49M 3.56M -0.01M -
Change to liabilities - - 1.81M 0.24M 0.02M
Total cashflows from investing activities -2.41M -0.49M 3.56M -0.01M -0.01M
Net borrowings - - 0.37M 0.49M -0.05M
Total cash from financing activities 2.76M 1.21M 1.35M -0.05M -0.05M
Net income 4.90M -12.80M -1.94M -0.49M -0.50M
Change in cash 6.64M -2.82M 3.78M 0.57M -0.15M
Begin period cash flow 1.03M 3.85M 0.07M 1.60M 1.75M
End period cash flow 7.67M 1.03M 3.85M 2.17M 1.60M
Total cash from operating activities 6.28M -3.56M -0.84M -0.51M 0.05M
Issuance of capital stock - 1.35M 0.58M - -
Depreciation 0.78M 0.26M 0.11M 0.03M 0.07M
Other cashflows from investing activities - -0.31M 3.62M 0.09M -
Change to inventory -1.95M -1.15M -0.92M -0.08M 0.40M
Change to account receivables -2.97M -1.22M -0.60M -0.27M 0.02M
Sale purchase of stock 2.45M 1.35M 0.58M 0.00M -
Other cashflows from financing activities 0.20M -0.14M 0.77M -0.05M -0.05M
Change to netincome - - 0.70M 0.13M 0.03M
Capital expenditures 2.41M 0.49M 0.06M 0.01M 0.03M
Change in working capital -4.92M -2.36M -1.51M -0.34M 0.41M
Stock based compensation 0.48M 0.14M 0.70M 0.10M -
Other non cash items 5.04M 11.34M 0.99M -0.04M 0.07M
Free cash flow 3.86M -4.05M -0.90M -0.51M 0.02M

Peer Comparison*

Sector: Consumer Defensive Industry: Packaged Foods

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
A2M
The a2 Milk Company Ltd		 -0.07
0.96%		 7.19 29.04 28.74 2.68 5.94 2.85 17.82
BGA
Bega Cheese Ltd		 -0.02
0.30%		 6.74 35.61 22.94 0.52 1.93 0.60 11.82
CBO
Cobram Estate Olives Ltd		 -0.06
2.26%		 2.59 - - 4.79 2.48 6.63 185.44
RIC
Ridley Corporation Ltd		 0.02
0.74%		 2.74 38.29 13.42 0.35 2.01 0.53 4.50

Profile*

Bioxyne Ltd

Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingredients and starting materials; plant-based food products, such as non-controlled cannabis extracts and cannabidiol; food grade mushroom extracts/psilocybin; medicinal and prescription cannabis products, including pastilles, vape, oral mucosal oils, flower, and suppositories; SL-NAD+ wafers; MDMA; white label manufactured wellness products; health and wellness supplements; and nootropic and skincare products. It also provides Lactobacillus fermentum VRI-003 PCC, a probiotic formulation for gastrointestinal health and immunity; Progastrim for gut and immune health; and proTract for atopic dermatitis. In addition, the company is involved in the contract manufacturing of final dose form products, including capsules, tablets, inhalables, oral solutions, and herbal preparations; import, export, manufacture, and supply of controlled drugs and medicinal products; research and development of formulations, products, and processes related to health, wellness, and medicine; and provision of telemedicine services. Further, it operates CanXChange, a machine-learning powered B2B wholesale and custody technology platform. The company offers its products to cultivators, manufacturers, pharmacies, clinics, and patients under the Breathe Life Science, Dr Watson, Mirai Solution, and Apothecary CBD brands. It sells its products through wholesale, retail, and online. Bioxyne Limited is headquartered in Sydney, Australia.

Level 5, Sydney, NSW, Australia, 2000

61 2 9078 8180

https://blspharma.com

Name Title Year Born
Mr. Nam Hoat Chua B.A., BA MD, CEO & Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), C.A., CA, MAICD CFO, Company Sec. & Exec. Director 1954
Ms. Rachel Qian Financial Controller & Assistant Company Sec. NA
Mr. Samuel Watson CEO, MD & Executive Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD CFO & Company Secretary 1953
Mr. Jason Hine COO & Executive Director NA
Ms. Rachel Qian Financial Controller & Assistant Company Secretary NA
Mr. Samuel Watson CEO, MD & Executive Director NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD CFO & Company Secretary 1953
Mr. Jason Hine COO & Executive Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…